Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B

Inclusion Criteria:

- Patients with haemophilia B with a FIX activity below or equal to 2%

- Male patients with moderately severe or severe congenital haemophilia B with a FIX
activity below or equal to 2% according to medical records

- History of at least 150 exposure days to other FIX products

- Scheduled major surgery

Exclusion Criteria:

- Known history of FIX (coagulation factor nine) inhibitors based on existing medical
records, laboratory report reviews and patient and LAR (legal acceptable
representative) interviews

- Current FIX (coagulation factor nine) inhibitors above or equal to 0.6 Bethesda Units
(central laboratory)

- Previous arterial thrombotic events (e.g. myocardial infarction and intracranial
thrombosis) or previous deep venous thrombosis or pulmonary embolism (as defined by
available medical records)

- ALT (alanine aminotransferase) 3 times the upper limit of normal reference ranges at
screening (central laboratory)

- Immune modulating or chemotherapeutic medication